{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:14:59Z","timestamp":1783530899590,"version":"3.55.0"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gr\u00fcnenthal de M\u00e9xico S.A. de C.V."},{"name":"Merz Therapeutics GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Cervical dystonia and spasticity are debilitating neuromuscular disorders that substantially impair quality of life. Botulinum toxin type A (BoNT-A) is a cornerstone therapy; however, heterogeneity in dosing, muscle selection, and guidance techniques can limit outcomes, and Mexico-specific practical guidance is limited. We convened a multidisciplinary panel of Mexican rehabilitation and neurology specialists with extensive experience in BoNT-A injection; recommendations were developed through a three-phase process: a targeted literature search, a structured online survey of Mexican rehabilitation and neurology specialists, and an in-person meeting (21 February 2025) where clinicians reviewed aggregated survey results and refined practical recommendations through structured deliberation. The manuscript provides pragmatic guidance on evaluation and goal setting, muscle selection, working dilutions, dosing ranges, and reinjection intervals, emphasizing ultrasound (US) and\/or electromyography (EMG) for deep or high-risk targets. It also summarizes key adverse events and proposes a stepwise approach to inadequate response, prioritizing reassessment of diagnosis, goals, targeting, and techniques before considering immunogenicity testing, product switching, or alternative interventions. These recommendations aim to improve standardization, safety, and goal attainment in routine Mexican practice.<\/jats:p>","DOI":"10.3390\/toxins18070287","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:56:55Z","timestamp":1782838615000},"page":"287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Botulinum Toxin Type A in Spasticity and Cervical Dystonia: Practical Clinical Recommendations from a Mexican Multidisciplinary Panel of Specialist Injectors"],"prefix":"10.3390","volume":"18","author":[{"given":"Jorge","family":"Hern\u00e1ndez Franco","sequence":"first","affiliation":[{"name":"National Institute of Neurology and Neurosurgery \u201cManuel Velasco Su\u00e1rez\u201d (INNN), Mexico City 14269, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador J.","family":"Santamar\u00eda Molina","sequence":"additional","affiliation":[{"name":"Mexican Social Security Institute (IMSS), National Medical Center La Raza, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 J.","family":"Zorrilla S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Teleton Children\u2019s Rehabilitation and Inclusion Center (CRIT), Mexico City 09868, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Carranza del R\u00edo","sequence":"additional","affiliation":[{"name":"Association for People with Cerebral Palsy (APAC), Mexico City 06720, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel S\u00e1nchez","family":"Villavicencio","sequence":"additional","affiliation":[{"name":"National Institute of Neurology and Neurosurgery \u201cManuel Velasco Su\u00e1rez\u201d (INNN), Mexico City 14269, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0492-8386","authenticated-orcid":false,"given":"Sof\u00eda D.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Institute for Social Security and Services for State Workers (ISSSTE), General Hospital Tacuba, Mexico City 11410, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Duvignau Dond\u00e9","sequence":"additional","affiliation":[{"name":"Pediatric Rehabilitation Center of the Armed Forces, M\u00e9rida 97196, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor A.","family":"Gonz\u00e1lez Usigli","sequence":"additional","affiliation":[{"name":"Mexican Social Security Institute (IMSS), Western National Medical Center (CMNO), Guadalajara 44329, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira S.","family":"Gonz\u00e1lez L\u00f3pez","sequence":"additional","affiliation":[{"name":"Teleton Children\u2019s Rehabilitation and Inclusion Center (CRIT), Mexico City 09868, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Leal Ortega","sequence":"additional","affiliation":[{"name":"Regional High Specialty Hospital of the Yucat\u00e1n Peninsula (HRAEPY), M\u00e9rida 97130, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azael A.","family":"Flores Salinas","sequence":"additional","affiliation":[{"name":"PHYSIS High-Specialty Rehabilitation, Chihuahua 31203, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A. Mej\u00eda","family":"Alonso","sequence":"additional","affiliation":[{"name":"Mexican Social Security Institute (IMSS), National Medical Center Siglo XXI, Mexico City 06720, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F. J. G\u00f3mez","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Teleton Children\u2019s Rehabilitation and Inclusion Center (CRIT), Mexico City 09868, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Fern\u00e1ndez Bravo","sequence":"additional","affiliation":[{"name":"Mexican Social Security Institute (IMSS), National Medical Center Siglo XXI, Mexico City 06720, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-3161","authenticated-orcid":false,"given":"Pedro I. Arias","family":"V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Academic Division of Health Sciences, Ju\u00e1rez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cimino, V., Chisari, C.G., and Patti, F. (2020). Spasticity and Dystonia: A Brief Review. Neurostimulation and Neuromodulation in Contemporary Therapeutic Practice, IntechOpen.","DOI":"10.5772\/intechopen.91780"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00702-020-02266-z","article-title":"Botulinum Toxin Therapy of Dystonia","volume":"128","author":"Dressler","year":"2021","journal-title":"J. Neural. Transm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00702-021-02312-4","article-title":"Consensus Guidelines for Botulinum Toxin Therapy: General Algorithms and Dosing Tables for Dystonia and Spasticity","volume":"128","author":"Dressler","year":"2021","journal-title":"J. Neural. Transm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/16501977-0303","article-title":"European Consensus Table on the Use of Botulinum Toxin Type A in Adult Spasticity","volume":"41","author":"Wissel","year":"2009","journal-title":"J. Rehabil. Med."},{"key":"ref_5","unstructured":"Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology, and Royal College of Occupational Therapists (2018). Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines, Royal College of Physicians. Available online: https:\/\/www.rcp.ac.uk\/media\/i1ijs0tm\/spasticity-in-adults_final-version_march-2019.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/pmrj.13211","article-title":"AAPM&R Consensus Guidance on Spasticity Assessment and Management","volume":"16","author":"Raghavan","year":"2024","journal-title":"PM&R"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4103\/2349-7904.347807","article-title":"Module 1: Pathophysiology and Assessment of Spasticity; Goal Setting","volume":"5","author":"Escaldi","year":"2022","journal-title":"J. Int. Soc. Phys. Rehabil. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0048-7120(09)72527-7","article-title":"Versi\u00f3n Espa\u00f1ola de la Gross Motor Function Measure (GMFM): Fase Inicial de su Adaptaci\u00f3n Transcultural","volume":"43","year":"2009","journal-title":"Rehabilitaci\u00f3n"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1161\/01.STR.0000105386.05173.5E","article-title":"Spasticity after Stroke: Its Occurrence and Association with Motor Impairments and Activity Limitations","volume":"35","author":"Sommerfeld","year":"2004","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"jrm00134","DOI":"10.2340\/16501977-2753","article-title":"A Practical Guide to Optimizing the Benefits of Post-Stroke Spasticity Interventions with Botulinum Toxin A: An International Group Consensus","volume":"53","author":"Francisco","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.toxcx.2020.100040","article-title":"High Clinician- and Patient-Reported Satisfaction with Individualized OnabotulinumtoxinA Treatment for Spasticity across Several Etiologies from the ASPIRE Study","volume":"7","author":"Francisco","year":"2020","journal-title":"Toxicon X"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PHM.0000000000002410","article-title":"Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study","volume":"103","author":"Bavikatte","year":"2024","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1212\/WNL.0000000000003789","article-title":"Safety and Efficacy of IncobotulinumtoxinA Doses up to 800 U in Limb Spasticity: The TOWER Study","volume":"88","author":"Wissel","year":"2017","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00702-014-1252-9","article-title":"Safety Aspects of IncobotulinumtoxinA High-Dose Therapy","volume":"122","author":"Dressler","year":"2015","journal-title":"J. Neural Transm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Xeomin US Blepharospasm Study Group. Sustained Efficacy and Safety of Repeated IncobotulinumtoxinA (Xeomin\u00ae) Injections in Blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_17","first-page":"100142","article-title":"Efficacy and Safety of Two IncobotulinumtoxinA Injection Intervals in Cervical Dystonia Patients with Inadequate Benefit from Standard Injection Intervals of Botulinum Toxin: Phase 4, Open-Label, Randomized, Noninferiority Study","volume":"6","author":"Comella","year":"2022","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yoo, M., Ahn, J.H., Rha, D.-W., and Park, E.S. (2022). Reliability of the Modified Ashworth and Modified Tardieu Scales with Standardized Movement Speeds in Children with Spastic Cerebral Palsy. Children, 9.","DOI":"10.3390\/children9060827"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s13018-024-04894-7","article-title":"Methods of Muscle Spasticity Assessment in Children with Cerebral Palsy: A Scoping Review","volume":"19","author":"Nourizadeh","year":"2024","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.18857\/jkpt.2017.29.3.115","article-title":"Functional Improvement after the Gross Motor Function Measure-88 (GMFM-88) Item-Based Training in Children with Cerebral Palsy","volume":"29","author":"Ko","year":"2017","journal-title":"J. Kor. Phys. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ejpn.2008.10.006","article-title":"Safety of Botulinum Toxin Type A in Children Younger than 2 Years","volume":"13","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kaya Kele\u015f, C.S., Bilgili, F., and Akdeniz Do\u011fan, Z.D. (2022). Botulinum Toxin Intervention in Cerebral Palsy-Induced Spasticity Management: Projected and Contradictory Effects on Skeletal Muscles. Toxins, 14.","DOI":"10.3390\/toxins14110772"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pediatrneurol.2020.10.014","article-title":"Assessments and Interventions for Spasticity in Infants with or at High Risk for Cerebral Palsy: A Systematic Review","volume":"118","author":"Ayala","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_24","first-page":"e48311","article-title":"Pain Management Strategies for Botulinum Toxin Type A Injections in Children: A Comprehensive National Survey and Procedural Protocol","volume":"15","author":"Moreira","year":"2023","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lazzaretto, V., Barbi, E., Carraro, C., Sutera, M., Celsi, F., Peri, F., and Zupin, L. (2025). Effectiveness of Pharmacological Procedural Sedation in Children with Cerebral Palsy Undergoing Botulinum Toxin Injection: A Systematic Review and Meta-Analysis. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1610064"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.24911\/SJP.106-1604549033","article-title":"Analgesia and Sedation Modalities Used with Botulinum Toxin Injections in Children with Cerebral Palsy: A Literature Review","volume":"21","author":"Nugud","year":"2021","journal-title":"Sudan. J. Paediatr."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration (2025, December 12). BOTOX\u00ae (OnabotulinumtoxinA) for Injection, for Intramuscular, Intradetrusor, or Intradermal Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103000s5320lbl.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.14412\/2074-2711-2022-2-117-125","article-title":"Russian Consensus on the Use of IncobotulinumtoxinA in Children with Cerebral Palsy for the Treatment of Spasticity and Sialorrhea","volume":"14","author":"Kurenkov","year":"2022","journal-title":"Neurol. Neuropsychiatry Psychosom."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (2025, December 12). XEOMIN\u00ae (IncobotulinumtoxinA) for Injection, for Intramuscular or Intraglandular Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125360s078lbl.pdf."},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (2025, December 12). DYSPORT\u00ae (AbobotulinumtoxinA) for Injection, for Intramuscular Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125274s115lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00702-019-02116-7","article-title":"Frequency of Different Subtypes of Cervical Dystonia: A Prospective Multicenter Study According to Col\u2013Cap Concept","volume":"127","author":"Jost","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/ayu.ayu_248_21","article-title":"Management of Cervical Dystonia through Ayurveda: A Case Report","volume":"44","author":"Prarthana","year":"2023","journal-title":"AYU"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1212\/01.WNL.0000142962.11881.26","article-title":"Capturing the True Burden of Dystonia on Patients: The Cervical Dystonia Impact Profile (CDIP-58)","volume":"63","author":"Cano","year":"2004","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/mds.29387","article-title":"Isolated Cervical Dystonia: Diagnosis and Classification","volume":"38","author":"Albanese","year":"2023","journal-title":"Mov. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pmr.2017.08.009","article-title":"Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia","volume":"29","author":"Kaymak","year":"2018","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fietzek, U.M., Nene, D., Schramm, A., Appel-Cresswell, S., Ko\u0161utzk\u00e1, Z., Walter, U., Wissel, J., Berweck, S., Chouinard, S., and B\u00e4umer, T. (2021). The Role of Ultrasound for the Personalized Botulinum Toxin Treatment of Cervical Dystonia. Toxins, 13.","DOI":"10.3390\/toxins13050365"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2019). Immunogenicity Associated with Botulinum Toxin Treatment. Toxins, 11.","DOI":"10.3390\/toxins11090491"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/7\/287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:26:17Z","timestamp":1783527977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/7\/287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["toxins18070287"],"URL":"https:\/\/doi.org\/10.3390\/toxins18070287","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}